Priority Review for Keytruda in MSI-H cancer

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab to treat advanced microsatellite instability-high (MSI-H) cancer. Its PDUFA date is March 8, 2017.

Merck is seeking accelerated approval of Keytruda in the indication based on data from five open-label Phase I/II trials...